Celgene

U.S. stocks rose after Federal Reserve boss Janet Yellen appeared in the hot-seat today speaking to the Committee on Financial Services and U.S. House of Representatives. Yellen said that it is too soon to determine the extent of which cold weather played a role in a recent batch of poor economic...

Among the leading biotech and emerging pharmaceutical companies, Amgen (NASDAQ: AMGN), Biogen Idec (NASDAQ: BIIB) and BioMarin Pharmaceutical (NASDAQ: BMRN) saw the largest percentage increases in short interest between the January 31 and February 15 settlement dates. Alexion Pharmaceuticals,...

Shares of the following exchange traded funds are trading more than 20 percent higher than 90 days ago, and they are within 10 percent of their 52-week highs. This set of ETFs provides a peek at areas of investor interest during and after the holiday shopping season, as uncertainty over the...

U.S. stocks finished higher on Thursday after a bumpy start to the trading session. “People want to buy the dips now because the market made a bottom after Feb. 3,” Donald Selkin, chief market strategist at National Securities Corp. told Bloomberg. “We got very oversold and now it's believed...

Among the leading biotech and emerging pharmaceutical companies, Incyte (NASDAQ: INCY) and Pharmacyclics (NASDAQ: PCYC) saw the largest percentage declines in short interest between the January 15 and January 31 settlement dates. Short sellers shied away from Alexion Pharmaceuticals, Amgen, Biogen...

Among the leading biotech and emerging pharmaceutical companies, Biogen Idec (NASDAQ: BIIB), BioMarin Pharmaceutical (NASDAQ: BMRN) and Medivation (NASDAQ: MDVN) saw the most significant upswings between the December 31 and January 15 settlement dates. Gilead Sciences, Pharmacyclics and Regeneron...

The earnings crunch is on this week. Highlights will include reports from Amazon.com, Apple, Boeing, Comcast, Facebook, Google and Yahoo! All of them are expected to report year-over-year growth in per-share earnings. But analysts are looking for declining profits from the likes of Caterpillar,...

The number of shares sold short in leading biotech and emerging pharmaceutical companies mostly declined between the December 13 and December 31 settlement dates. BioMarin Pharmaceutical (NASDAQ: BMRN), Celgene (NASDAQ: CELG) and Dendreon (NASDAQ: DNDN) led that trend. Short sellers also shied...

For the first time in the new year, markets ended the day on a positive note. While it is only a few days in, markets appear to have started off 2014 on uncertain footing. Investors and traders found some positives in the U.S. trade deficit which fell to its lowest level in four years, an...

Among leading biotech and emerging pharmaceutical companies, the number of shares sold short in Amgen (NASDAQ: AMGN), Gilead Sciences (NASDAQ: GILD) and Pharmacyclics (NASDAQ: PCYC) grew by the largest percentages between the November 29 and December 13 settlement dates. Medivation saw its short...

Among leading biotech and emerging pharmaceutical companies, the number of shares sold short in Biogen Idec (NASDAQ: BIIB), Celgene (NASDAQ: CELG) and Pharmacyclics (NASDAQ: PCYC) grew by the largest percentages in late November. Gilead Sciences, Regeneron Pharmaceuticals, Seattle Genetics and...

Stock futures pointed to a lower open following premarket data revealing that the U.S. economy and job market are improving faster and stronger than expected. Selling began at the bell and continued for the entire day as major indices failed to hold on to any rallying gains. Investors and...

Among leading biotech and emerging pharmaceutical companies, the number of shares sold short in Alexion Pharmaceuticals (NASDAQ: ALXN), BioMarin Pharmaceutical (NASDAQ: BMRN) and Gilead Sciences (NASDAQ: GILD) grew by the largest percentages in late October. Biogen Idec (NASDAQ: BIIB), Illumina...

Among leading biotech and emerging pharmaceutical companies, short sellers retreated from Biogen Idec (NASDAQ: BIIB) by the largest percentage in early October. Amgen (NASDAQ: AMGN), Illumina (NASDAQ: ILMN), Regeneron Pharmaceuticals (NASDAQ: REGN) and Seattle Genetics (NASDAQ: SGEN) saw short...

Among leading biotech and emerging pharmaceutical companies, short sellers moved on Amgen (NASDAQ: AMGN), Pharmacyclics (NASDAQ: PCYC) and Vertex Pharmaceuticals (NASDAQ: VRTX) the most strongly in late September. The number of shares sold short in Dendreon (NASDAQ: DNDN) and Biogen Idec (NASDAQ:...